Castle Biosciences (CSTL) CCO Juvenal Tobin Sells 1,730 Shares

What Happened
Juvenal Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), sold 1,730 shares in an open-market transaction on 2026-08-31. The weighted-average sale price was $32.81, producing gross proceeds of approximately $56,761. This was a sale (not a purchase or option exercise) and was executed under a pre-established trading program.

Key Details

• Transaction date: 2026-08-31 (reported on Form 4 filed 2026-09-02).
• Shares sold: 1,730; weighted-average price: $32.81; total proceeds: ~$56,761.
• Price range / trade execution: multiple trades at $32.39–$33.17; reported price is the weighted average (filing offers to provide per-trade details on request).
• Plan/authorization: Transaction made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2025.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Filing timeliness: Form 4 filed within the normal post-trade reporting window (filed 2026-09-02 for 2026-08-31 trades).

Context
A 10b5-1 plan lets insiders sell shares according to a prearranged schedule and generally reduces the likelihood that the trades reflect contemporaneous, nonpublic company knowledge. Sales are often routine and less informative about management’s view of the company than purchases, though they are relevant for monitoring insider activity.